JARID1B Antibodies

Target Information

Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor for FOXG1B and PAX9. Favors the proliferation of breast cancer cells by repressing tumor suppressor genes such as BRCA1 and HOXA5. In contrast, may act as a tumor suppressor for melanoma. Represses the CLOCK-ARNTL/BMAL1 heterodimer-mediated transcriptional activation of the core clock component PER2. Belongs to the JARID1 histone demethylase family. Ubiquitously expressed, with highest levels in testis. Down-regulated in melanoma and glioblastoma. Up-regulated in breast cancer (at protein level). 2 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

[histone H3]-trimethyl-L-lysine(4) demethylase 5B; Cancer/testis antigen 31; CT31; FLJ10538; FLJ12459; FLJ12491; FLJ16281; FLJ23670; Histone demethylase JARID1B; JARID1B; jumonji, AT rich interactive domain 1B; Jumonji/ARID domain-containing protein 1B; KDM5B; lysine (K)-specific demethylase 5B; lysine demethylase 5B; Lysine-specific demethylase 5B; MRT65; PLU-1; PLU1; PPP1R98; protein phosphatase 1, regulatory subunit 98; PUT1; putative DNA/chromatin binding motif; RBBP2H1; RBBP2H1A; RBP2-H1; RBP2-like; Retinoblastoma-binding protein 2 homolog 1; retinoblastoma-binding protein 2, homolog 1A